Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,967.38
(
0.00%
)
US TECH 100
25,130.40
(
-0.05%
)
Dow Jones
48,535.99
(
0.00%
)
Brent Oil
92.91
(
-2.68%
)
Bitcoin
74,287.28
(
0.12%
)
News Focus
News Focus
Post# of 821321
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Couch

Send PM Follow Ignore
Followers 280
Posts 31200
Boards Moderated 0
Alias Born 07/06/2012

Couch

Re: ManicTrader post# 158731

Tuesday, 10/27/2015 7:12:26 AM

Tuesday, October 27, 2015 7:12:26 AM

Post# of 821321
ELTP Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200 Meets Primary and Secondary Endpoints

http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Elite intends to submit a New Drug Application to the U.S. Food and Drug Administration for abuse-deterrent ELI-200 by year-end.

Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today